Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection

Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection

Tuberculosis (TB) remains a main public health concern and 10.4 million new cases occurred in 2015 around the world. BCG is the only approved vaccine against TB, but has variable efficacy and new vaccines are needed. We developed two new mTB vaccine candidates based on the recombinant fusion protein...

Full description

Bibliographic Details
Main Authors: Bruno de Paula Oliveira Santos, Monalisa Martins Trentini, Renato Beilner Machado, Mara Rúbia Nunes Celes, André Kipnis, Nikolai Petrovsky, Ana Paula Junqueira-Kipnis
Format: Article
Language:English
Published: Taylor & Francis Group 2017-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
tuberculosis
vaccine
adjuvant
tb
ecmx
advax
delta inulin
Online Access:http://dx.doi.org/10.1080/21645515.2017.1368598

Internet

http://dx.doi.org/10.1080/21645515.2017.1368598

Similar Items